2009 Fiscal Year Final Research Report
Identification of tumor antigen derived peptides having the potential to promise candidates for cancer vaccine therapy from prostate cancer patients
| Project/Area Number |
20791130
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kinki University |
|---|
Principal Investigator |
MINAMI Takafumi Kinki University, 医学部, 助教 (70340809)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Keywords | 前立腺癌 / 癌ワクチン / HLA-A3 / supertype / alleles |
|---|
| Research Abstract |
Peripheral blood mononuclear cells(PBMCs) were obtained from prostate cancer patients who had provided a written informed consent. Fifty milliliter of peripheral blood was obtained, and the PBMCs were prepared by Ficoll-Conray density gradient centrifugation. The expression of HLA-A11,-A31,and -A33 molecules on the PBMCs was determined by flow cytometry using these antibodies-anti-HLA-A11, anti-HLA-A31, anti-HLA-A33-and FITC-conjugated anti-mouse immunoglobulin G(IgG) monoclonal antibodies.
7 prostate cancer-related antigens(SART2, CypB, PTH-rP, HER2neu, EGFR, MRP3, EZH2) prepared based on the binding motifs to the MHC-class I alleles.
To generate LNCaP sublines expressing each of the HLA-A11, -A31, and-A33 molecules, an HLA-A1101, -A3101, or. A3303 plasmid cDNA was inserted into the eukaryotic expression vector pCR3.1.
20 patient's peripheral blood mononuclear cells(PBMCs) were obtained from prostate cancer patients. The expression of HLA-A11, -A31, -A33 molecules on the PBMCs was determined by flow cytometry using these antibodies.
|
